Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571–578.

    Article  Google Scholar 

  2. Sauter CS, Lechner L, Scordo M, Zheng J, Devlin SM, Fleming SE et al. Pre-transplant FDG-PET scan lacks prognostic value in chemosensitive b-cell non-Hodgkin lymphoma patients undergoing non-myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 881–884.

    Article  Google Scholar 

  3. Dodero A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F et al. Pretransplantation [18-F] fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer 2010; 116: 5001–5011.

    Article  Google Scholar 

  4. Lambert JR, Bomanji JB, Peggs KS, Thomson KJ, Chakraverty RK, Fielding AK et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. Blood 2010; 115: 2763–2768.

    Article  CAS  Google Scholar 

  5. Tomblyn M, Brunstein C, Burns LJ, Miller JS, MacMillan M, DeFor TE et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 538–545.

    Article  Google Scholar 

  6. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  Google Scholar 

  7. Peniket AJ, Ruiz de Elvira MC, Taghipour G, Cordonnier C, Gluckman E, de Witte T et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003; 31: 667–678.

    Article  CAS  Google Scholar 

  8. Yoshimi A, Izutsu K, Takahashi M, Kako S, Oshima K, Kanda Y et al. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Am J Hematol 2008; 83: 477–481.

    Article  Google Scholar 

  9. Ram R, Gooley TA, Maloney DG, Press OW, Pagel JM, Petersdorf SH et al. Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011; 17: 1537–1545.

    Article  Google Scholar 

  10. Cheson BD, Fisher RI, Barrington S, Zucca E, Cavalli F, Lister TA . Follow-up of the 11-ICML workshop on lymphoma staging and restaging in PET-CT era. Hematologic Oncology 2013; 31: S1 (abstract 128).

    Google Scholar 

Download references

Acknowledgements

This work was supported in part by NIH P30 CA77598 utilizing the biostatistics and informatics core, Masonic Cancer Center, University of Minnesota shared resource, and the Janie Lymphoma Fund (LJB). Research reported in this publication was also in part supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (VB).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V Bachanova.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bachanova, V., Cao, Q., Ustun, C. et al. Pretransplantation fluorine-18-deoxyglucose-positron emission tomography scan has no influence on relapse and survival in non-Hodgkin lymphoma patients undergoing allo-SCT. Bone Marrow Transplant 50, 142–144 (2015). https://doi.org/10.1038/bmt.2014.211

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.211

Search

Quick links